How Suboxone Treatment Works

You have heard that the film is "just another opioid," and you are trying to tell a myth from a medicine that might keep you alive. Suboxone is a brand of film that contains two medicines: buprenorphine and naloxone. The FDA says buprenorphine is a partial opioid agonist and naloxone is an opioid antagonist, and that the film is indicated for the treatment of opioid dependence. The same label says it should be part of a complete plan that includes counseling and psychosocial support. The myths are what get people hurt. No dose, induction calendar, or home start is listed here. Methadone, buprenorphine, and naltrexone are compared on the medication FAQ. The subject here is the combination film.

If breathing is slow, the person will not wake, or the lips look blue, call 911 and use naloxone if you have the overdose-reversal medicine. That naloxone is a separate product. It is not the naloxone inside the film. That response is on the overdose guide. For a mental health crisis, call or text 988.

What the partial agonist does

SAMHSA calls buprenorphine the first medicine for opioid use disorder that can be prescribed or dispensed in a physician's office, which widened access beyond a specialty clinic. The agency describes it as an opioid partial agonist. At low to moderate doses it can produce effects such as euphoria or slowed breathing, but those effects are weaker than the effects of full opioid agonists such as heroin. SAMHSA says that when it is taken as prescribed, it is safe and effective, that it diminishes withdrawal and craving, and that one of its pharmacological properties is increased safety in cases of overdose.

Read that last line next to the warnings, not instead of them. SAMHSA also says buprenorphine can be misused, particularly by people who do not have an opioid dependency. Mixing it with alcohol, illegal drugs, sedatives, tranquilizers, or other drugs that slow breathing can lead to overdose or death. The FDA label says the film is not appropriate as a pain medicine, and that deaths have been reported in opioid-naive people, meaning people not already taking opioids, who received a sublingual dose. "Weaker than heroin" is not "impossible to overdose."

NIDA's broader point, which applies to buprenorphine and to methadone, is that these medicines reduce craving and withdrawal without the intense high of heroin or fentanyl when they are taken as prescribed. NIDA also says people treated with methadone or buprenorphine are less likely to die or to overdose than people who do not receive those treatments. That is a population finding. It is not a promise about one person, and it is not a reason to skip the overdose-reversal medicine. The FDA says clinicians should strongly consider recommending or prescribing an overdose-reversal agent, such as naloxone or nalmefene, when the film is started or renewed, because a return to other opioids is still possible. Keep that medicine where it can be reached, including if children or other people in the home could take the film by mistake. The label says buprenorphine can cause severe, possibly fatal, slowed breathing in children. Store the film out of their sight and reach. Do not share it with someone who has "the same problem."

Why naloxone is in the strip

SAMHSA says naloxone is added to buprenorphine to decrease the chance that the combination product will be diverted or misused. The FDA warning is specific: an opioid withdrawal syndrome is likely if someone who is physically dependent on a full opioid agonist injects the film, or if they take it under the tongue or in the cheek before the effects of other opioids have worn off. That second path is called precipitated withdrawal. It can be severe. It is why "I'll just take a piece and see" is a bad experiment.

The label also says the film must be taken whole. Do not cut, chew, or swallow it. That is a safety instruction from the prescribing information, not a how-to for getting started. The label's milligram schedule, the day-by-day induction, and any later adjustment belong to the prescriber. FDA has also told the public that older label wording was misread as a maximum daily dose when the labeling does not set one, and that the dose should be adjusted to the individual. Those milligram figures stay in the label. Choosing a number from an article is how people precipitate withdrawal or take more than a clinician intended.

SAMHSA says that to begin treatment, a person needs to be in the early stages of opioid withdrawal, after time without other opioids, because opioids still in the body can trigger acute withdrawal. The FDA says induction should wait until objective, clear signs of withdrawal are evident. People moving from methadone or other long-acting opioids are a special case: the label says combination products were not adequately studied for induction in that group, and that buprenorphine alone is what the label recommends for those first days, with a later switch to the combination film. Do not make that switch from a friend's instructions.

A federal X-waiver is no longer required to prescribe buprenorphine. The DEA has told registrants that, as of December 29, 2022, prescriptions use an ordinary DEA number and the old federal patient caps are gone. The DEA also says the change does not override state law. You still need a prescriber who is allowed to prescribe where you live. How that differs from methadone, which for opioid use disorder comes through an opioid treatment program, is on the medication FAQ.

Counseling, pregnancy, and stopping

The FDA indication is not the film by itself, with no other care. It says the film should be used as part of a complete treatment plan that includes counseling and psychosocial support. SAMHSA says the same thing in its own words: prescribe it as part of a comprehensive plan that includes counseling and other services. Counseling is not a punishment for taking a medicine. It is part of the labeled use.

Pregnancy is a reason to call the prescriber, not a reason to flush the film. SAMHSA says buprenorphine may be prescribed for pregnant patients with opioid use disorder, and that buprenorphine and methadone are considered the treatments of choice in pregnancy and during breastfeeding. The FDA label says neonatal opioid withdrawal syndrome is an expected and treatable outcome of prolonged opioid use in pregnancy. More of that picture is on the pregnancy guide. Tell the clinician. Do not stop on the day of a positive test.

The label says there is no maximum recommended length of maintenance treatment. Patients may need it indefinitely, as long as they are benefiting and the medicine still serves the treatment goals. SAMHSA says the duration is tailored, and that treatment can be indefinite in some cases. If a house, a court, or a relative tells you to stop in order to prove you are serious, that demand is not the label. Stopping abruptly can cause withdrawal. The FDA says to taper gradually when treatment ends, and to monitor people if doses are interrupted. The taper is the prescriber's job. Do not cut the film to improvise one.

Common effects SAMHSA lists include constipation, headache, nausea, and vomiting. Tell the prescriber about effects that do not fade, about liver disease, and about every other medicine, including benzodiazepines. The label says to warn patients not to add benzodiazepines or other depressants on their own.

FindTreatment.gov can locate programs and prescribers. Call or text (800) 653-9376 if you need help finding care that continues buprenorphine rather than stopping it at the door.

Additional Resources

Sources cited on this page:

• FDA label: SUBOXONE (buprenorphine and naloxone) sublingual film, revised December 2025
• SAMHSA: Buprenorphine
• NIDA: Medications for Opioid Use Disorder
• NIDA: Misconceptions about maintenance treatment
• FDA: Labeling changes for transmucosal buprenorphine products for opioid use disorder
• DEA: Elimination of the DATA-Waiver requirement
• SAMHSA FindTreatment.gov
• 988 Suicide & Crisis Lifeline

Common Questions